Literature DB >> 28427101

Tanshinol Alleviates Osteoporosis and Myopathy in Glucocorticoid-Treated Rats.

Guanghua Chen1, Xinle Zhang2, Han Lin3, Guizhi Huang1, Yahui Chen2, Liao Cui2,4.   

Abstract

Tanshinol is a major water-soluble active component of Salvia miltiorrhiza. In this study, we aimed to investigate whether tanshinol has potential therapeutic effects against glucocorticoid-induced osteoporosis and glucocorticoid-induced myopathy. Ninety-six female Sprague-Dawley rats were randomly assigned to five groups: a control group, a model group, and three model groups treated with 25 or 50 mg/kg of tanshinol, or calcitriol. All model groups received prednisone acetate for 90 days to induce glucocorticoid-induced osteoporosis. Afterwards, all animals underwent a surgical procedure to induce bone defects at the right proximal tibia. Prednisone treatment was stopped after surgery, but tanshinol or calcitriol treatment was continued to the endpoint. At the experimental endpoint, compared to the model group, 25 mg/kg tanshinol could significantly reverse glucocorticoid-induced loss of bone mineral density by 12.5 %, while enhancing mechanical bone strength, causing a significant 11 % increase in trabecular number, and reducing trabecular separation by 28 %. In addition, tanshinol improved the bone microarchitecture and prevented glucocorticoid-induced bone loss by promoting bone formation and inhibiting bone resorption. Moreover, results of bone defect repair and muscle weight measurements revealed that tanshinol accelerated the bone fracture healing process and attenuated muscle atrophy caused by glucocorticoid. Furthermore, qRT-PCR analysis showed a 1-fold upregulation in mRNA levels of transforming growth factor beta and roughly 6-fold increases in vascular endothelial growth factor mRNA expression in calluses from the tanshinol groups. Tanshinol also preserved muscular ubiquitin mRNA levels from glucocorticoid-induced elevation. These findings demonstrate the potential benefits of tanshinol against glucocorticoid-induced osteoporosis and glucocorticoid-induced myopathy, which warrants further investigation in future studies. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28427101     DOI: 10.1055/s-0043-108761

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  6 in total

1.  Animal Model for Glucocorticoid Induced Osteoporosis: A Systematic Review from 2011 to 2021.

Authors:  Andy Xavier; Hechmi Toumi; Eric Lespessailles
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

2.  Antiosteoporosis effect of tanshinol in osteoporosis animal models: A systematic review and meta-analysis.

Authors:  Shen Wang; Yifeng Yuan; Qian Lin; Hang Zhou; Binbin Tang; Yang Liu; Hai Huang; Bocheng Liang; Yingdelong Mao; Kang Liu; Xiaolin Shi
Journal:  Front Pharmacol       Date:  2022-08-10       Impact factor: 5.988

3.  Bone-Targeting Liposome-Encapsulated Salvianic Acid A Improves Nonunion Healing Through the Regulation of HDAC3-Mediated Endochondral Ossification.

Authors:  Limin Zhou; Haojun Wu; Xiang Gao; Xiaoyan Zheng; Hang Chen; Hailong Li; Jun Peng; Weichong Liang; Wenxing Wang; Zuocheng Qiu; Anjaneyulu Udduttula; Kefeng Wu; Lin Li; Yuyu Liu; Yanzhi Liu
Journal:  Drug Des Devel Ther       Date:  2020-08-26       Impact factor: 4.162

Review 4.  Bone Health and Natural Products- An Insight.

Authors:  Vasanti Suvarna; Megha Sarkar; Pramila Chaubey; Tabassum Khan; Atul Sherje; Kavitkumar Patel; Bhushan Dravyakar
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

5.  Plant Extracts in the Bone Repair Process: A Systematic Review.

Authors:  Lyvia Lopes Miranda; Vanessa de Paula Guimarães-Lopes; Luciana Schulthais Altoé; Mariáurea Matias Sarandy; Fabiana Cristina Silveira Alves Melo; Rômulo Dias Novaes; Reggiani Vilela Gonçalves
Journal:  Mediators Inflamm       Date:  2019-11-25       Impact factor: 4.711

6.  Tanshinol alleviates ulcerative colitis by promoting the expression of VLDLR.

Authors:  Huanhuan Zhu; Shaopeng Tong; Yan Cui; Xiaodong Wang; Minying Wang
Journal:  Drug Dev Res       Date:  2021-06-18       Impact factor: 5.004

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.